Cencora, Inc. (COR)

In the past six months, Cencora's stock reached an all-time high closing price of $374.11 on November 25, 2025. In February 2026, Cencora's shares jumped by 7.1% following its first-quarter fiscal year 2026 results, which surpassed profit expectations, and the company raised its full-year guidance. In May 2026, Cencora reported its second-quarter fiscal year 2026 results, which led to a decline in its stock price because the adjusted diluted EPS of $4.75 missed the consensus estimate of $4.80, and revenue of approximately $78.36 billion trailed analyst estimates of around $81.09 billion. Consequently, Cencora shares hit a new 52-week low of $244.82 after the quarter.

Demand for Cencora's products and services exhibits seasonality, particularly for certain pharmaceutical categories. There is typically increased demand for cold and flu remedies during the winter months. The summer season often sees higher demand for products like antifungal creams and sunscreen lotions. The monsoon season can lead to a surge in demand for dermatological products. Over-the-counter medications, such as seasonal allergy and cold remedies, can experience unpredictable demand shifts influenced by factors like weather changes. Pharmaceutical clinical trials can also experience peak periods of activity.

Cencora, Inc., formerly AmerisourceBergen, is a global pharmaceutical services company in the Healthcare sector, specifically within the Medical Distribution industry. Its core business involves sourcing and distributing pharmaceutical products, including branded, generic, and specialty pharmaceuticals, as well as over-the-counter healthcare products, home healthcare supplies, and equipment. Cencora provides healthcare solutions and services, including global specialty drug logistics through World Courier, animal health product distribution via MWI Animal Health, and commercialization services for manufacturers of pharmaceuticals and medical devices. The company operates through two main segments: U.S. Healthcare Solutions and International Healthcare Solutions.

Cencora has a significant global presence, operating in over 50 countries with more than 1,300 global office locations and distribution centers. The company has a strong presence across North and South America, Europe, and Asia Pacific, with over 50 U.S. distribution centers, enabling it to deliver therapies and care worldwide.

Cencora's brand reputation has been shaped by its strategic rebranding and ongoing challenges. The company rebranded from AmerisourceBergen to Cencora in August 2023, reflecting its expanding global footprint. The company emphasizes its commitment to corporate responsibility, sustainability, and ethical supply chain practices. However, Cencora has faced significant reputation-related events, including liabilities from its multi-billion dollar opioid litigation settlement and a cyberattack in February 2024 that exposed sensitive patient data.

Cencora's ownership is predominantly held by institutional investors, who collectively own approximately 97.52% of the company's stock. Major institutional shareholders include The Vanguard Group, Inc., BlackRock, Inc., State Street Corporation, T. Rowe Price Group, Inc., Geode Capital Management, LLC, Boston Partners, Wellington Management Group LLP, and J.P. Morgan Asset Management. Walgreens Boots Alliance is also a significant shareholder, although it has been reducing its stake in the company. Individual insiders collectively own less than 1% of the company.